According to a new study by King’s College London, involving patients in the design and implementation of research programmes increases the likelihood of studies recruiting to target. Delays in recruitment are a major reason why some studies fail, so better recruitment means studies are more likely to be successful and run on time and budget. The authors argue that researchers need to involve patients more comprehensively in research.
Published in the British Journal of Psychiatry, the researchers analysed 374 studies registered with the Mental Health Research Network (MHRN). Studies which included collaboration with service users in designing or running the trial were 1.63 times more likely to recruit to target than studies which only consulted service users. Studies which involved more partnerships – a higher level of Patient and Public Involvement (PPI) – were 4.12 times more likely to recruit to target.
More information can be found at http://www.kcl.ac.uk/iop/news/records/2013/September/Patient-involvement-in-research-boosts-study-success.aspx and http://brc.slam.nhs.uk/our-blog/brcu/developing-best-treatments-means-patient-involvement-every-step-of-the-way
Paper reference: Ennis, L. et al. ‘Impact of patient involvement in mental health research: longitudinal study’ British Journal of Psychiatry (Sept 2013) doi: 10.1192/bjp.bp.112.119818
Free Patient and Public Involvement training for Parkinson’s researchers
Patient and Public Involvement Seminar Series










New Nepal scoping review on maternal & neonatal health
Fourth INRC Symposium: From Clinical Applications to Neuro-Inspired Computation
Writing policy briefs
Upholding Excellence: The Concordat to Support Research Integrity
ECR Funding Open Call: Research Culture & Community Grant – Application Deadline Friday 12 December
MSCA Postdoctoral Fellowships 2025 Call
ERC Advanced Grant 2025 Webinar
Horizon Europe Work Programme 2025 Published
Horizon Europe 2025 Work Programme pre-Published
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease